Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BG 60366

Next Previous
X
Search
Drug Profile

BG 60366

Alternative Names: BG-60366; Chimeric degradation activating compound (CDAC) targeting EGFR - BeiGene

Latest Information Update: 31 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Class Antineoplastics; Small molecules
  • Mechanism of Action ErbB receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer

Most Recent Events

  • 26 Nov 2024 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT06685718)
  • 12 Nov 2024 BeiGene plans a phase Ia/b trial for Non-small cell lung cancer (Second-line therapy or greater, Metastatic disease, late-stage disease) in December 2024 (PO) (NCT06685718)
  • 13 Aug 2024 BG 60366 is available for licensing as of 13 Aug 2024. https://www.beigene.com/about/partnering/

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top